369 related articles for article (PubMed ID: 23737653)
1. Update on the protective molecular pathways improving pancreatic beta-cell dysfunction.
Puddu A; Sanguineti R; Mach F; Dallegri F; Viviani GL; Montecucco F
Mediators Inflamm; 2013; 2013():750540. PubMed ID: 23737653
[TBL] [Abstract][Full Text] [Related]
2. Combination of TS-021 with metformin improves hyperglycemia and synergistically increases pancreatic β-cell mass in a mouse model of type 2 diabetes.
Tajima A; Hirata T; Taniguchi K; Kondo Y; Kato S; Saito-Hori M; Ishimoto T; Yamamoto K
Life Sci; 2011 Oct; 89(17-18):662-70. PubMed ID: 21872612
[TBL] [Abstract][Full Text] [Related]
3. Treating type 2 diabetes: incretin mimetics and enhancers.
Janosz KE; Zalesin KC; Miller WM; McCullough PA
Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):387-95. PubMed ID: 19808944
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes.
Mari A; Del Prato S; Ludvik B; Milicevic Z; de la Peña A; Shurzinske L; Karanikas CA; Pechtner V
Diabetes Obes Metab; 2016 Aug; 18(8):834-9. PubMed ID: 27059816
[TBL] [Abstract][Full Text] [Related]
5. Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.
Otsuka Y; Yamaguchi S; Furukawa A; Kosuda M; Nakazaki M; Ishihara H
Endocr J; 2015; 62(2):133-43. PubMed ID: 25328079
[TBL] [Abstract][Full Text] [Related]
6. [Protective effects of glucagon-like peptide-1 on beta-cells: preclinical and clinical data].
Consoli A; Di Biagio R
G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):5-9. PubMed ID: 22158421
[TBL] [Abstract][Full Text] [Related]
7. Incretin effects on β-cell function, replication, and mass: the human perspective.
Garber AJ
Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S258-63. PubMed ID: 21525465
[No Abstract] [Full Text] [Related]
8. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
Campbell RK
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
[TBL] [Abstract][Full Text] [Related]
9. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
Schwasinger-Schmidt T; Robbins DC; Williams SJ; Novikova L; Stehno-Bittel L
Pharmacol Res; 2013 Oct; 76():58-66. PubMed ID: 23891763
[TBL] [Abstract][Full Text] [Related]
10. Metformin induces insulin secretion by preserving pancreatic aquaporin 7 expression in type 2 diabetes mellitus.
Kimura T; Kaneto H
J Diabetes Investig; 2022 Feb; 13(2):227-229. PubMed ID: 34779127
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
Liu Y; Hong T
Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of prediabetes in clinical practice: targeting insulin resistance and β-cell dysfunction.
Armato J; DeFronzo RA; Abdul-Ghani M; Ruby R
Endocr Pract; 2012; 18(3):342-50. PubMed ID: 22068250
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic beta-cell mass and function and therapeutic implications of using antidiabetic medications in type 2 diabetes.
Moon JH; Choe HJ; Lim S
J Diabetes Investig; 2024 Jun; 15(6):669-683. PubMed ID: 38676410
[TBL] [Abstract][Full Text] [Related]
14. Investigational agents that protect pancreatic islet beta-cells from failure.
Aston-Mourney K; Proietto J; Andrikopoulos S
Expert Opin Investig Drugs; 2005 Oct; 14(10):1241-50. PubMed ID: 16185166
[TBL] [Abstract][Full Text] [Related]
15. Protection of pancreatic beta-cells: is it feasible?
Bonora E
Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
[TBL] [Abstract][Full Text] [Related]
16. beta-cell failure in diabetes and preservation by clinical treatment.
Wajchenberg BL
Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
[TBL] [Abstract][Full Text] [Related]
17. Impact of three oral antidiabetic drugs on markers of β-cell function in patients with type 2 diabetes: a meta-analysis.
Lu J; Zang J; Li H
PLoS One; 2013; 8(10):e76713. PubMed ID: 24204660
[TBL] [Abstract][Full Text] [Related]
18. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
19. The effects of glucagon-like peptide-1 on the beta cell.
Vilsbøll T
Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():11-8. PubMed ID: 19878257
[TBL] [Abstract][Full Text] [Related]
20. Sodium-glucose cotransporter-2 inhibition improves incretin sensitivity of pancreatic β-cells in people with type 2 diabetes.
Ahn CH; Oh TJ; Kwak SH; Cho YM
Diabetes Obes Metab; 2018 Feb; 20(2):370-377. PubMed ID: 28786557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
